SUPN - Supernus resubmits NDA for Parkinson's disease infusion device
2023-10-09 17:37:36 ET
More on Supernus Pharmaceuticals
- Supernus: Product Sales Stretching Higher, But Not Reflected In Economic Leverage
- Supernus Pharmaceuticals, Inc. (SUPN) Q2 2023 Earnings Call Transcript
- EU regulators warn pregnant women not to use topiramate
- Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals
- Historical earnings data for Supernus Pharmaceuticals
For further details see:
Supernus resubmits NDA for Parkinson's disease infusion device